Rheumatology Journals

Rheumatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Balint, G.P., et al. - Overactivity of IL-6 plays a very important role in both the exsudative and proliferative phase of rheumatoid inflammation, joint destruction and osteoporosis. Blocking of IL-6 activity is a rational goal in the treatment of rheumatoid arthritis (RA). Tocilizumab (TCZ) is a humanized antibody against the soluble IL-6 receptor (sIL-6R) and membrane-bound IL-6 receptor (mIL-6R), blocking these receptor complexes and preventing IL-6 transmembrane signaling


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address